Rorer Group Inc's ArmourPharmaceutical Co said it received Food and Drug Administrationapproval for a blood clotting drug for hemophiliacs.    The company said the drug, monoclate antihemophilic factor,will treat hemophilia A, the most common form of hereditaryblood clotting disorder.    Monoclate is 99 pct free of unwanted contaminants, comparedto other blood products which are less than one pct pure,Armour said. Reuter&#3;